AIM ImmunoTech Inc. issued a stockholder letter from Chief Executive Officer Thomas Equels positioning its drug Ampligen as a potential complement to daraxonrasib following the U.S. Food and Drug Administration's recent approval of daraxonrasib for metastatic pancreatic cancer. The letter notes that a pivotal randomized study showed daraxonrasib achieved median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, an improvement of 6.5 months, but that many patients on both treatments still experience disease progression and mortality. Ampligen, a TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment, has a different mechanism of action from daraxonrasib, which selectively inhibits RAS. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months versus 12.5 months in well-matched historical controls, an observed increase of 22.3 months. AIM also said its ongoing Phase 2 DURIPANC trial is evaluating Ampligen with AstraZeneca's durvalumab in patients whose pancreatic cancer was stable post-FOLFIRINOX, with topline results anticipated in Q1 2027 and a detailed overall survival analysis in Q3 2027.
AIM ImmunoTech IncAIM's stockholder letter positions Ampligen as a potential complement to daraxonrasib, citing its distinct TLR3-agonist mechanism and 34.8-month median OS in the Dutch Named Patient Program analysis.
Revolution Medicines IncThe FDA approved daraxonrasib, Revolution Medicines' RAS-selective inhibitor, for metastatic pancreatic cancer based on a pivotal trial showing 13.2 vs 6.7 months median OS.
AstraZeneca PLCAstraZeneca's durvalumab is only mentioned as the combination partner in AIM's ongoing Phase 2 DURIPANC trial, with no new AstraZeneca-specific development.
